Drug intelligence / Profile preview

CanVirex01

Development stage: Preclinical
Lead developer: CanVirex
Modality: Gene Silencing → Gene Therapies, Oncolytic Viruses → Oncolytic Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
Administration: Intratumoral, Intravenous

Overview

CanVirex01 is a pre-clinical stage oncolytic virus immunotherapy developed by CanVirex. It utilizes a measles virus vector platform designed to selectively infect, replicate within, and lyse malignant cells, thereby releasing tumor-associated antigens and stimulating a robust anti-tumor immune response. The candidate is the lead asset in CanVirex's oncology program, with clinical trial initiation projected for 2027.

Other names: CanVirex01CanVirex-01CanVirex 01

Targets

SLAMF1 (SLAM family member 1)PVRL4 (Nectin cell adhesion molecule 4)IL-12R (Interleukin-12 receptor)

Beyond the preview

Go deeper on CanVirex01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CanVirex01.

Explore the full profile